KAILERA THERAPEUTICS INC (KLRA)
Health Care · Obesity / weight loss therapeutics · NASDAQ
A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential.
What KAILERA THERAPEUTICS INC does
Kailera Therapeutics is a clinical-stage biotechnology company focused on obesity care, advancing a diversified pipeline of GLP-1-based product candidates designed to address critical needs in obesity management. The company's lead candidate, ribupatide injection (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 trials for weight loss. The company also develops ribupatide oral (once-daily tablet), KAI-7535 (oral small molecule GLP-1 agonist), and KAI-4729 (once-weekly injectable GLP-1/GIP/glucagon tri-agonist), all licensed through a strategic collaboration with Hengrui Pharmaceuticals with exclusive rights outside Greater China.
Themes: ["GLP-1 / obesity treatment","weight loss medications","obesity care pipeline"]
Fundamentals
- Price$21.01 as of 2026-07-09 close
- Market cap$2.8B as of 2026-07-10
- 1-year return-16.3% as of 2026-07-09 close
- ROE-23.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.41 as of 2026-07-10
Key risks (from latest filing)
["All product candidates remain in clinical development and regulatory approval is not guaranteed; company has not conducted head-to-head trials against approved products or competitors","Extensive development timeline required before commercialization of any product candidate; company is pre-revenue clinical stage with no approved products","Dependence on strategic collaboration with Hengrui Pharmaceuticals for product development and commercialization in Greater China regions"]
Competitors & peers
- Eli Lilly (obesity/diabetes franchises)
- Novo Nordisk (GLP-1 agonists - Saxenda, Ozempic, Wegovy)
- Viking Therapeutics
- Structure Therapeutics
- Zealand Pharma
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.